Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Medical Polymer Market worth $66.29 billion by 2030 - Exclusive Report by…
357 - Tables 357 - Tables 54 - Figures 450 - Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=211635984 Various factors affect the medical polymer market, and it is important to note that they are an indication of advances in the healthcare, materials science, and patient care fields. There is a growing demand for lightweight, durable, and biocompatible materials for medical devices, production of everything from implants to surgical...
PR Newswire
05/09/2025
2025 Ashwagandha Market Analysis Report to 2030 by Mordor Intelligence
Innovation in Convenient Formats Innovation in Convenient Formats Gummies and chews are transforming consumer adoption, growing at over 12% CAGR, as younger demographics and busy professionals favor on-the-go formats. Capsules, tablets, and powders remain significant, while liquid extracts cater to urban wellness markets. Functional Foods & Beverages on the Rise Ashwagandha's integration into teas, protein shakes, and fortified snacks is expanding its consumer base beyond...
PR Newswire
05/09/2025
Midea Redefines Dishwashing at IFA with the Launch of Revolutionary GreenApex…
Complementing this achievement, the TITAN Dishwasher reimagines space utilization and cleaning performance. Through precision engineering—including an 18% leaner pump system—it offers 26% more upper rack capacity within the same elegant footprint. The "Micro-shell, Macro-capacity" design enhance space efficiency while the zone-specific washing system delivers targeted, spotless results. Whether hosting gatherings or enjoying daily meals, users can now rely on TITAN for powerful…
PR Newswire
05/09/2025
Breaking: the SHURUI® Single-Port Surgical Robot Receives its CE Certification
The SHURUI® Single-Port Surgical Robot's unique snake-like instrument technology enables multi-degree of freedom, high-precision operations through a single skin incision, drastically reducing surgical trauma and accelerating patient recovery. Its advanced intelligent motion control and surgeon-friendly interface provide safe, precise, and intuitive operations across complex adult and pediatric procedures. Surgeons can now perform procedures that previously required multiple incisions using just…
PR Newswire
05/09/2025
Czech MedTech Startup Unveils World's First Patented Hydrogen-Based Therapy with…
"This is not another experiment — it is the first technology in the world with the potential to prevent Alzheimer's disease before it even starts, while supporting those already affected," saysDavid Marsalek, founder and CEO ofH2 Global Group. The company believes its effectiveness will be further confirmed in an upcoming new clinical trial. "Our mission is clear: toturn decades of research into real hope for millions of familiesaround the world. We are part of a strong...
PR Newswire
05/09/2025
Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in…
MUMBAI, India, Sept. 5, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd., a research-led, global pharmaceutical company, today announced the initiation of a multi-country (ex-China) Phase 3 Clinical Trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III Non-Small Cell Lung Cancer (NSCLC) in the neoadjuvant/adjuvant setting. The Company has received approval from the Drugs Controller General of India (DCGI) to begin patient enrollment and dosing in…
PR Newswire
05/09/2025
GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the…
GLP-1 Agonists Market Summary GLP-1 Agonists Market Summary Discover which indication is expected to grab the major GLP-1 agonists market share @GLP-1 Agonists Market Report Key Factors Driving the Growth of the GLP-1 Agonists Market Rising Prevalence of Type 2 Diabetes and Obesity GLP-1 agonists have emerged as a game-changing therapy for managing obesity and diabetes, offering significant benefits in weight loss and glycemic control. With obesity affecting over650...
PR Newswire
05/09/2025
KingSmith Introduces WalkingCase, a New Generation of Treadmill at IFA Berlin…
KingSmith also introduced two other upcoming innovations. The FC216 Incline Treadmill brings uphill training home with up to 10% automatic incline and KingSmith's patented Vertical Fold for easy, space-saving storage. The three-fold WMX Water and Magnetic Rower combines a bold asymmetric frame with 50 kg adjustable magnetic resistance, delivering powerful, customizable cardio training in a compact design. KingSmith also introduced two other upcoming innovations. TheFC216 Incline Treadmill...
PR Newswire
05/09/2025
SOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership…
The hospital will implement six SOPHiA GENETICS applications tailored to its testing needs in solid tumors, hematologic malignancies, and liquid biopsy analysis, enhancing both clinical decision-making and research capabilities. The hospital will implement six SOPHiA GENETICS applications tailored to its testing needs in solid tumors, hematologic malignancies, and liquid biopsy analysis, enhancing both clinical decision-making and research capabilities. The SOPHiA GENETICS solution combines...
PR Newswire
05/09/2025
NexLawn Unveils Arm-Equipped Robotic Mowers and Smart Yard Lineup at IFA 2025
The VIDAR and VIDAR AWD Series will launch in Europe and North America in spring 2026. At the exhibition, NexLawn partnered with MOVA to showcase smart yard innovations, with MOVA presenting its gardening tools and NexLawn highlighting its future plans. The VIDAR and VIDAR AWD Series will launch inEuropeandNorth Americain spring 2026. At the exhibition, NexLawn partnered with MOVA to showcase smart yard innovations, with MOVA presenting its gardening tools and NexLawn highlighting its...
PR Newswire
05/09/2025
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
COPENHAGEN, Denmark, September 5, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 3,818,710 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. The shares were subscribed for in cash at the following prices per share of nominally DKK 10: 363,156 shares at DKK 206.82 and 18,715 shares at DKK 190...
Nasdaq GlobeNewswire
05/09/2025
Novo Nordisk to present new semaglutide data on ‘food noise’, body composition…
The INFORM real-world evidence study shows impact of semaglutide on reducing ‘food noise’, and the STEP UP clinical trial highlights semaglutide’s effect on control of eating and body composition after losing weightNext-generation obesity treatment cagrilintide demonstrates promise as standalone therapy (REDEFINE 1); data also being presented on amycretinThe first head-to-head real-world study, REACH shows superiority of Ozempic ®versus dulaglutide on cardiovascular events such as heart...
Nasdaq GlobeNewswire
05/09/2025
Idorsia to collaborate with two leading academic medical centers to launch…
Multi-phase program to standardize treatment, generate real-world evidence and explore AI-powered tools to improve outcomes for hypertension patientsAllschwil, Switzerland & Radnor, Philadelphia – September 5, 2025Idorsia Ltd (SIX: IDIA) announces a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a new three-phase program to transform and modernize the management of difficult-to-control hypertension. Patients requiring...
Nasdaq GlobeNewswire
05/09/2025
Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to…
"This is about creating new options for patients facing some of the toughest cancers," said Jill German, Head of Pathology Lab at Roche Diagnostics. "Our understanding of HER2 is rapidly evolving, and this expanded approval ensures our diagnostics are leading the way. We're enabling clinicians to unlock personalized, life-altering treatments for patients who urgently need them." "This is about creating new options for patients facing some of the toughest cancers,"…
PR Newswire
05/09/2025
Dr Batra's® Brings Specialised XOGEN Advance Treatment to UAE, powered with 36…
Commenting on the launch, Dr.Akshay Batra, Trichologist and Managing Director, Dr Batra's® Healthcare, said: "At Dr Batra's®, we are committed to bringing the world's latest innovations to our patients across the UAE. Hair loss has over 40 causes, from genetics to lifestyle. XOGEN Advance stands out because it not only delivers faster and more effective results but also addresses the root cause with our unique combination of advanced aesthetics and homeopathy. This ensures safe,...
PR Newswire
05/09/2025
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in…
In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end 1 Over 60% of people with a difficult-to-treat form of nAMD showed no signs of damaging lesions in the SALWEEN study, and clinically meaningful vision improvements were observed 2 Vabysmo was well tolerated with a consistent long-term safety profile in nAMD in both studies Basel, 05 September...
Nasdaq GlobeNewswire
05/09/2025
Gaucher's Disease Market to Witness Significant Upswing During the Forecast…
Gaucher's Disease Market Summary Gaucher's Disease Market Summary Discover the Gaucher's disease new treatment @New Treatments for Gaucher's Disease Key Factors Driving the Growth of the Gaucher's Disease Market Rising Gaucher's Disease Incidence and Awareness Gaucher's disease, though rare, is the most common lysosomal storage disorder. Its incidence is increasing due to heightened awareness, improved diagnostic capabilities, and the expansion of genetic testing...
PR Newswire
04/09/2025
Inventiva to Participate in Upcoming September Investor Conferences
Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events: H.C. Wainwright 27th Annual Global Investment ConferenceDate:...
Nasdaq GlobeNewswire
04/09/2025
Steven Mickelsen, MD, Launches Del Medtech to Expand Pulsed Field Ablation…
Del Medtech is developing transformative, single-use ablation devices designed to improve efficiency and patient outcomes. With initial focus areas in GI, ENT, men's and women's health, and oncology, the company is targeting market opportunities with annual revenues ranging from $1.4 billion to $7.4 billion and projected growth rates between 9 percent and 13 percent. Del Medtech is developing transformative, single-use ablation devices designed to improve efficiency and patient outcomes...
PR Newswire
04/09/2025
Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing…
BioTrack Capital and Yonjin Capital join Series A round alongside other investors including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam CapitalUpsized and over-subscribed Series A total funding of $44 million securedRapafusyn’s RapaGlue™ platform rapidly discovers non-degrading molecular glues, a validated and highly sought-after modality to address challenging disease targets BALTIMORE, MD, Sept.04, 2025(GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals, a leader in...
Nasdaq GlobeNewswire
04/09/2025
Maxima Grupė‘s First Half of 2025: Slower Revenue Growth and Moderate…
The consolidated revenue of companies managed by MAXIMA GRUPĖ, UAB in the first half of 2025 grew by 3.5% compared to the same period last year, reaching €3.07 billion. Consolidated like-for-like (LFL) retail revenue, calculated at constant exchange rates, increased by 2.3%. The slowdown in overall Group revenue growth compared to previous year was driven by several factors. The biggest challenge for faster revenue growth in the Baltic states was the slowdown of the Latvian and Estonian...
Nasdaq GlobeNewswire
04/09/2025
Avania Strengthens Leadership Team with Appointment of Four New Executives
Avania, the leading global MedTech advisory and clinical development partner, is pleased to announce strategic leadership appointments of four distinguished executives. As the MedTech industry navigates increasing regulatory complexity and technological innovation, these new leaders bring decades of combined experience in clinical research, regulatory affairs, operations, information technology, and business development, further reinforcing Avania’s commitment to excellence and growth...
Nasdaq GlobeNewswire
04/09/2025
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
/ XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced, in collaboration with EURETINA, the winner of the Ramin Tadayoni Award 2025.The Ramin Tadayoni Award honors the next generation of ophthalmologists by supporting an exceptional postgraduate scholar in retina research. It was established in 2024 in memory of the late Professor Ramin Tadayoni, Oculis’ former Chief...
Nasdaq GlobeNewswire
04/09/2025
Probiotics Market Hits USD 108 Billion in 2031, Driven by Preventive Healthcare…
Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/probiotics-market Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response):https://www.datamintelligence.com/download-sample/probiotics-market Japan Market (2024) Japanstands out as thelargest probiotics market inAsia-Pacific , valued at approximately USD 9.1 billionin 2024. The market is deeply entrenched in...
PR Newswire
04/09/2025
Altri Comunicati